Improvement of Cardiac Function in Thalassemia major Treated with L-Carnitine

Introduction: Heart disease secondary to chronic anemia and hemosiderosis remains the major cause of morbidity and mortality in thalassemic patients. Chronic anemia and the tissue hypoxia it induces impair free fatty acid oxidation and ATP production in myocardial cells. The use of L-carnitine, a butyric acid derivative, may help overcome some of these defects. Objective: To investigate the effect of L-carnitine therapy on cardiac function in thalassemia major patients. Materials and Methods: Cardiac function was evaluated in 30 patients attending our clinic. The mean (±SD) age was 15.87 ± 3.19 years. The studies we performed included echocardiography, Doppler and multigated equilibrium radionuclide angiography (MUGA). Systolic and diastolic function was evaluated before starting L-carnitine treatment and after 6 months of oral L-carnitine (50 mg/kg/day). Results: Echocardiography studies revealed no significant changes in systolic and diastolic function after L-carnitine therapy (p > 0.05). Analysis of the data taken by MUGA performed in 20 of the patients, however, showed a significant improvement of diastolic function after 6 months of L-carnitine therapy. The mean peak filling rate (end-diastolic volume/s) increased from 3.15 ± 1.06 to 3.61 ± 1.68 (p < 0.03). The time to peak (during filling) decreased significantly from 143.45 ± 42.04 to 117.70 ± 24.40 s (p < 0.02). Systolic function showed a significant increase in the left ventricular ejection fraction from 58.25 ± 9.92 to 63.95 ± 10.11% (p = 0.0001). Conclusion:L-Carnitine may be an effective drug for improving the cardiac status of thalassemic patients. MUGA is the most accurate technique of those used here for assessing left ventricular function in these patients.

[1]  K. Huber,et al.  Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis , 1996, European Journal of Nuclear Medicine.

[2]  R. Ferrari,et al.  Acute and Chronic Effects of Propionyl-L-Carnitine on the Hemodynamics, Exercise Capacity, and Hormones in Patients with Congestive Heart Failure , 1998, Cardiovascular Drugs and Therapy.

[3]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia ☆ , 2003 .

[4]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[5]  K. Mavromatidis,et al.  THE INFLUENCE OF l-CARNITINE SUPPLEMENTATION ON HEMATOCRIT AND HEMOGLOBIN LEVELS IN PATIENTS WITH END STAGE RENAL FAILURE ON CAPD , 2002, Renal failure.

[6]  G. Henze,et al.  Oral isobutyramide reduces transfusion requirements in some patients with homozygous β-thalassemia , 2000 .

[7]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[8]  P. Colonna,et al.  Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial , 2000 .

[9]  G. Henze,et al.  Oral isobutyramide reduces transfusion requirements in some patients with homozygousb-thalassemia , 2000 .

[10]  N. Akar,et al.  Evaluation of cardiac functions in patients with thalassemia major , 1999, Annals of nuclear medicine.

[11]  O. Yeǧin,et al.  L-Carnitine Treatment in Beta Thalassemia Major , 1998, Acta Haematologica.

[12]  M. Jessup,et al.  Diagnosis and Management of Iron‐induced Heart Disease in Cooley's Anemia , 1998, Annals of the New York Academy of Sciences.

[13]  S. Kothari,et al.  L-carnitine in children with idiopathic dilated cardiomyopathy. , 1998, Indian heart journal.

[14]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[15]  A. Desideri,et al.  Left ventricular function in thalassemia major: protective effect of deferoxamine. , 1994, The Canadian journal of cardiology.

[16]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[17]  P. Toutouzas,et al.  Left ventricular diastolic Doppler characteristics in beta-thalassemia major. , 1993, Circulation.

[18]  L. Landini,et al.  Quantitative Ultrasonic Analysis of Myocardium in Patients With Thalassemia Major and Iron Overload , 1993, Circulation.

[19]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[20]  R. Agarwal,et al.  Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: a combined M-mode, two-dimensional, and Doppler echocardiographic study. , 1992, American heart journal.

[21]  P. Stein,et al.  Left Atrial Contribution to Ventricular Filling During the Course of Evolving Heart Failure , 1992, Circulation.

[22]  J R Stratton,et al.  Four radionuclide methods for left ventricular volume determination: comparison of a manual and an automated technique. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  C. Pepine.  The therapeutic potential of carnitine in cardiovascular disorders. , 1991, Clinical therapeutics.

[24]  G. Lupi,et al.  Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. , 1990, Circulation.

[25]  A. Hoffbrand,et al.  High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. , 1990, Acta haematologica.

[26]  I. Murray,et al.  Sustained normalization of cardiac function by chelation therapy in thalassaemia major. , 1989, Clinical and laboratory haematology.

[27]  A. Piga,et al.  SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.

[28]  P. Farci,et al.  [Echocardiographic study at rest and during effort in adult asymptomatic thalassemic patients]. , 1989, Cardiologia.

[29]  P. Corr,et al.  Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. , 1989, The Journal of clinical investigation.

[30]  P. Toutouzas,et al.  Global and Segmental Left Ventricular Function in β-Thalassemia , 1985 .

[31]  P. Toutouzas,et al.  Global and segmental left ventricular function in beta-thalassemia. , 1985, Cardiology.

[32]  I. McDonald.  Echocardiographic Assessment of Left Ventricular Function in Aortic Valve Disease , 1976, Circulation.